[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.41.181. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 1993

Pentoxifylline Increases Retinal Capillary Blood Flow Velocity in Patients With Diabetes

Author Affiliations

From the Departments of Ophthalmology and Cell Biology, Duke University Medical Center, and Durham Veterans Affairs Medical Center, Durham, NC (Drs Sonkin and Hatchell and Mr Kelly), and Department of Ophthalmology, Hahnemann University School of Medicine, Philadelphia, Pa (Dr Sinclair). Dr Sonkin is currently a resident in the Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas. The authors have no personal or financial interests in the materials or methods used in this study.

Arch Ophthalmol. 1993;111(12):1647-1652. doi:10.1001/archopht.1993.01090120069024
Abstract

Objective:  The purpose of this study was to determine whether oral pentoxifylline would improve retinal microvascular hemodynamics and blood rheology in patients with diabetes.

Design:  Patients were enrolled in a double-masked, placebocontrolled trial of pentoxifylline at 2000 mg/d. Retinal capillary blood velocity and leukocyte density, filterability, viscosity, and fibrinogen content were measured by the bluefield entoptic phenomenon simulation, filtration, rotational viscosimetry, and heat precipitation techniques, respectively, before, during, and after drug therapy.

Results:  Treatment with pentoxifylline resulted in a 23.2%, 26.8%, and 37.8% increase in capillary blood flow velocity at 1, 2, and 3 months of therapy, respectively, with a return to pretreatment baseline levels 1 month after cessation of therapy. There were no apparent effects on the remaining variables during treatment.

Conclusion:  Pentoxifylline increases retinal capillary blood flow velocity in patients with diabetes.

References
1.
DeVaro J, Chumdermpodetsuk R, Edelman R, Sinclair S, MacGregor RR.  Polymorphonuclear (PMN) filterability in diabetes mellitus . Invest Ophthalmol Vis Sci . 1988;29:181.
2.
Ernst E, Matrai A.  Altered red and white blood cell rheology in type II diabetes . Diabetes . 1986;35:1412-1415.Article
3.
Freedman SF, Hatchell DL.  Enhanced superoxide radical production by stimulated polymorphonuclear leukocytes in a cat model of diabetes . Exp Eye Res . 1992;55:767-773.Article
4.
Schröder S, Palinski W, Schmid-Schönbein GW.  Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy . Am J Pathol . 1991;139:81-100.
5.
Sonkin PL, Freedman SF, Needham D, Rao KMK, Hatchell DL.  Pentoxifylline modulates deformability, F-actin content, and superoxide anion production of polymorphonuclear leukocytes from diabetic cats . Exp Eye Res . 1992;55:831-838.Article
6.
Sonkin PL, Sinclair SH, Hatchell DL.  Pentoxifylline improves retinal capillary blood flow velocity and whole blood viscosity . Am J Ophthalmol . 1993;115:775-780.
7.
Kelly LW, Barden CA, Tiedeman JS, Hatchell DL.  Alterations in viscosity and filterability of whole blood and blood cell subpopulations in diabetic cats . Exp Eye Res . 1993;56:341-347.Article
8.
Millar HR, Simpson JG, Stalker AL.  An evaluation of the heat precipitation method for plasma fibrinogen estimation . J Clin Pathol . 1971;24:827-830.Article
9.
Riva CE, Petrig B.  Blue field entoptic phenomenon and blood velocity in the retinal capillaries . J Opt Soc Am . 1980;70:1234-1238.Article
10.
Sinclair SH, Azar-Cavanagh M, Soper KA, Tuma RF, Mayrovitz HN.  Investigation of the source of the blue field entoptic phenomenon . Invest Ophthalmol Vis Sci . 1989;30:668-673.
11.
Schmid-Schönbein GW, Skalak R, Usami S, Chien S.  Cell distribution in capillary networks . Microvasc Res . 1980;19:18-44.Article
12.
Mayrovitz HN.  The relationship between leukocyte and erythrocyte velocity in arterioles . In: Bagge U, Born GVR, Gaehtgens P, eds. White Blood Cells, Morphology, and Rheology Related to Function . The Hague, the Netherlands: Nijhoff; 1982:82-88.
13.
Mayrovitz HN. Rubin R.  Leukocyte distribution to arteriolar branches: dependence on microvascular blood flow . Microvasc Res . 1985;9:282-294.Article
14.
Sinclair SH.  Macular retinal capillary hemodynamics in diabetic patients . Ophthalmology . 1991;98:1580-1586.Article
15.
Robinson F, Chen S, Petrig BL, Grunwald JE, Riva CE.  The acute effect of topical epinephrine on macular blood flow in humans . Invest Ophthalmol Vis Sci . 1992;33:18-22.
16.
Robinson F, Petrig BL, Sinclair SH, Riva CE, Grunwald JE.  Does topical phenylephrine, tropicamide, or proparacaine affect macular blood flow? Ophthalmology . 1985;92:1130-1132.Article
17.
Lotfi K, Grunwald JE, Furubavashi C.  The effect of caffeine on the human macular circulation . Invest Ophthalmol Vis Sci . 1990;31:567.
18.
Nash GB, Thomas PRS, Dormandy JA.  Abnormal flow properties of white blood cells in patients with severe ischaemia of the leg . BMJ . 1988;296:1699-1701.Article
19.
Vermes I, Steinmetz ET, Zeyen LJJM, van der Veen EA.  Rheological properties of white blood cells are changed in diabetic patients with microvascular complications . Diabetologia . 1987;30:434-436.Article
20.
Wierusz-Wysocka B, Wysocki H, Siekierta H, Wykretowiez A, Szczepanik A, Klimas R.  Evidence of polymorphonuclear neutrophils (PMN) activation in patients with insulin-dependent diabetes mellitus . J Leukoc Biol . 1987;42:519-523.
21.
Andersen B, Goldsmith GH, Spagnuolo P.  Neutrophil adhesive dysfunction in diabetes mellitus: the role of cellular and plasma factors . J Lab Clin Med . 1988;111:275-285.
22.
Kohner EH.  Retinal ischemia . In: Ryan SJ, Schacat AP, Murphy RP, Patz A, eds. Retina . St Louis, Mo: Mosby-Year Book; 1989;2:89-97.
23.
Ehrly AM.  Improvement of the flow properties of blood: a new therapeutical approach in occlusive arterial disease . Angiology . 1976;27:188-196.Article
24.
Schubotz R, Mühlfellner O.  The effect of pentoxifylline on erythrocyte deformability and on phosphatide fatty acid distribution in the erythrocyte membrane . Curr Med Res Opin . 1977;4:609-617.Article
25.
Angelkort B, Maurin N, Boateng K.  Influence of pentoxifylline on erythrocyte deformability in peripheral occlusive arterial disease . Curr Med Res Opin . 1979;6:255-258.Article
26.
Gaillard S, Schooneman F, Voisin P, et al.  Effects compares sur la filtrabilite in vivo chez l'homme de deux formes galeniques de la pentoxifylline . Ann Med Nancy . 1979;18:1099-1102.
27.
Manrique RV, Manrique V.  Platelet resistance to prostacyclin: enhancement of the antiaggregatory effect of prostacyclin by pentoxifylline . Angiology . 1987;38:101-108.Article
28.
Sonkin PL, Chen LE, Seaber AV, Hatchell DL.  Vasodilator action of pentoxifylline on microcirculation of rat cremaster muscle . Angiology . 1992;43:462-469.Article
29.
Katusic ZS, Vanhoutte PM.  Superoxide anion is an endothelium-derived contracting factor . Am J Physiol . 1989;257(Heart Circ Physiol 26):H33-H37.
30.
Cogan DG, Merola L, Laibson PR.  Blood viscosity, serum hexosamine and diabetic retinopathy . Diabetes . 1961;10:393-395.
31.
Hoare EM, Barnes AJ, Dormandy JA.  Abnormal blood viscosity in diabetes mellitus and retinopathy . Biorheology . 1976;13:21-25.
32.
Rao KMK, Simel DL, Cohen HJ, Crawford J, Currie MS.  Effects of pentoxifylline administration on blood viscosity and leukocyte cytoskeletal function in patients with intermittent claudication . J Lab Clin Med . 1990;115:738-744.
33.
Rössner M, Müller R.  On the assessment of the efficacy of pentoxifylline (Trental) . J Med . 1987;18:1-15.
34.
Aviado DM, Porter JM.  Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects . Pharmacotherapy . 1984;4:297-307.
35.
Schubotz R.  Double-blind trial of pentoxifylline in diabetics with peripheral vascular disorders . Pharmatherapeutica . 1976;1:172-179.
36.
Ehrly AM.  Effects of orally administered pentoxifylline on muscular oxygen pressure in patients with intermittent claudication . IRCS J Med Sci . 1982;19:401-402.
37.
Porter JM, Cutler BS, Lee BY, et al.  Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients . Am Heart J . 1982;104:66-72.Article
38.
Insel J, Halle AA, Mirvis DM.  Efficacy of pentoxifylline in patients with stable angina pectoris . Angiology . 1988;39:514-519.Article
39.
Hartmann A, Tsuda Y.  A controlled study on the efficacy of pentoxifylline and an ergot alkaloid derivative on regional cerebral blood flow in patients with chronic cerebrovascular disease . Angiology . 1988;39:449-457.Article
40.
Schultheiss R, Leuwer R, Leniger-Follert E, Wassmann H, Wüllenweber R.  Tissue p02 of human brain cortex: method, basic results and effects of pentoxifylline . Angiology . 1987;38:221-225.Article
41.
Herskovits E, Famulari A, Tamaroff L, et al.  Preventive treatment of cerebral transient ischemia: comparative randomized trial of pentoxifylline versus conventional antiaggregants . Eur Neurol . 1985;24:73-81.Article
42.
Wolfe KA, Sebag J, Sadun AA, Brown S, Tang M, Charles MA.  Effects of pentoxifylline on ocular blood flow in non-proliferative diabetic retinopathy . Invest Ophthalmol Vis Sci . 1991;32:863.
43.
Ferrari E, Fioravanti M, Patti AL, Viola C, Solerte SB.  Effects of long-term treatment (4 years) with pentoxifylline on haemorheological changes and vascular complications in diabetic patients . Pharmatherapeutica . 1987;5:26-39.
×